Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
CellAct Pharma GmbH
With
Mundipharma-EDO GmbH
A phase II evaluation will be performed in adult patients in parallel studies in 3 tumor types: NSCLC, SCLC and Biliary Tract Cancer. All patients will have advanced or metastatic disease with primary or secondary resistance to standard therapy. In each tumor type the patients will be randomized to receive either therapy with CAP7.1 or best supportive care according to institution standards. Patient in the Control group who progress may cross over to CAP7.1, however these patients will be analyzed separately from the patients randomized to CAP7.1.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically- or cytologically-confirmed, advanced disease with documented progression (RECIST1.1.) after one or several chemotherapy line
Patients may also have received molecular targeted therapy and progressed while on therapy or after completion
Must have recovered from the acute reversible effects of previous anti-cancer chemotherapy, usually 3-4 weeks after myelosuppressive chemotherapy
You may not be if
Serious concurrent medical condition, which could affect compliance with the protocol or interpretation of results.